M&A is back, but how often do deals pay off?
A combination of Covid and market gloom results in the fewest acquisitions closing for over 20 years.
M&A is back on the menu, but there are still reasons to be cautious.
Deal making in biosimilars dominates a slow start to the year for biopharma M&A.
Cancer, rare diseases and neurology targets account for a big chunk of biopharma's buyouts, with interest showing no sign of waning.
Companies with late-stage assets have been attracting ever higher price tags over the past five years, Evaluate Vantage finds.
Biopharma's growing appetite for higher-risk areas prompts a shift in dealmaking strategies, our latest deep dive into M&A data finds.
Biopharma takeouts in the $1-5bn range jumped in 2021, as rising valuations made their mark.
Small and mid-sized developers upped deal-making activity last year, a deep dive into M&A data finds.